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More than 130 different mutations in the gap junction integral plasma membrane protein con-
nexin32 (Cx32) have been linked to the human peripheral neuropathy X-linked Charcot–Marie–
Tooth disease (CMTX). How these various mutants are processed by the cell and the mecha-
nism(s) by which they cause CMTX are unknown. To address these issues, we have studied the
intracellular transport, assembly, and degradation of three CMTX-linked Cx32 mutants stably
expressed in PC12 cells. Each mutant had a distinct fate: E208K Cx32 appeared to be retained in
the endoplasmic reticulum (ER), whereas both the E186K and R142W mutants were transported
to perinuclear compartments from which they trafficked either to lysosomes (R142W Cx32) or
back to the ER (E186K Cx32). Despite these differences, each mutant was soluble in nonionic
detergent but unable to assemble into homomeric connexons. Degradation of both mutant and
wild-type connexins was rapid (t1/2 , 3 h) and took place at least in part in the ER by a process
sensitive to proteasome inhibitors. The mutants studied are therefore unlikely to cause disease by
accumulating in degradation-resistant aggregates but instead are efficiently cleared from the cell
by quality control processes that prevent abnormal connexin molecules from traversing the
secretory pathway.
INTRODUCTION
Charcot–Marie–Tooth (CMT) 1 disease is the name given to
a heterogeneous group of dominant disorders that collec-
tively are the most common form of inheritable disease in
the peripheral nervous system (Murakami et al., 1996). The
X-linked form of CMT 1 disease (CMTX) is a progressive
demyelinating neuropathy characterized clinically by mod-
erately reduced nerve conductance velocities. Manifesta-
tions of CMTX typically include weakness and atrophy of
the distal limb muscles, sensory loss in feet, lower legs, and
hands, pes cavus deformity, and decreased or absent deep
tendon reflexes (reviewed by Bone et al., 1997). The severity
of symptoms varies considerably between affected families
and in males ranges from mild impairment to being wheel-
chair-bound by age 50 y (Ionasescu et al., 1996; Deschenes et
al., 1997).
In 1993, CMTX was genetically linked to defects in the
gene encoding the tetra-spanning integral plasma mem-
brane protein connexin32 (Cx32) (Bergoffen et al., 1993).
Cx32, like other members of the connexin protein family,
forms gap junctions in vertebrate tissues. Gap junctions are
collections of transmembrane channels that serve as low-
resistance pathways for the diffusion of substances ,1 kDa
in molecular mass including ions, metabolites, and second
messengers (Goodenough et al., 1996). Usually, gap junc-
tions form between two neighboring cells, creating intercel-
lular conduits that relay messages between, and maintain
metabolic continuity within, connected cells. In contrast,
uninjured myelinating Schwann cells do not make gap junc-
tions with each other or with neuronal cells. Instead, Cx32
appears to form gap junctions between adjoining wraps of
myelin within the sheath of a single Schwann cell at the
incisures of Schmidt–Lanterman and the paranodal region.
This creates a radial pathway for the diffusion of substances
that has been estimated to be up to 1000 times shorter than
the circumferential route (Scherer et al., 1995; Balice-Gordon
et al., 1998). Although the function of these intracellular gap
junctions is unclear, possibilities include dissipation of po-
tassium gradients generated by neuronal activity and trans-
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myelin transport of small trophic and signaling molecules.
Mice with a targeted deletion of the Cx32 gene, although
normal when young, gradually develop a progressive de-
myelinating neuropathy with histological features similar to
those observed in human CMTX patients (Anzini et al., 1997;
Scherer et al., 1998).
More than 130 different mutations in Cx32 have been
identified in CMTX patients (Bone et al., 1997). Essential to
elucidating the molecular mechanisms underlying CMTX
and the basis for genotype and phenotype correlations is
determining how defects in the Cx32 gene disrupt connexin
function. The great majority of CMTX-linked Cx32 muta-
tions result in changes in single amino acid residues that
could affect channel formation, activity, and/or metabolic
stability. As determined from structural and biochemical
analysis, the first step in gap junction formation is the non-
covalent oligomerization of six connexin monomers into a
hexameric annular structure known as a connexon. After
transport to the cell surface, two connexons on apposing
plasma membranes dock to form what is usually an inter-
cellular channel, but which in Schwann cells instead links
adjacent myelin wraps. Last, these channels pack at up to
10,000/mm2 into paracrystallin arrays known as gap junc-
tional plaques (reviewed by Musil, 1994). Despite this com-
plex assembly process, there is no evidence that gap junction
formation requires any nonconnexin protein(s). Another re-
markable aspect of gap junctions is the rapid turnover rate of
connexins, which are degraded in a wide variety of cultured
and in vivo systems with a t1/2 of only 1.5–5 h even after
incorporation into gap junctional plaques (Fallon and Good-
enough, 1981; Musil et al., 1990; Beardslee et al., 1998).
To date, it has not been possible to maintain either endog-
enous or exogenous Cx32 protein expression in cultured
Schwann cells (Scherer et al., 1995; Yoshimura et al., 1998),
necessitating the use of other systems for the in vitro study
of CMTX-linked Cx32 mutants. When transfected into oth-
erwise connexin-deficient PC12 cells, several Cx32 point mu-
tants, including R142W, E186K, and E208K, showed no de-
tectable staining on the plasma membrane but instead
appeared to be defective in intracellular transport (De-
schenes et al., 1997). The R142W Cx32 mutant also accumu-
lated intracellularly when expressed under the control of the
myelin-specific Po promotor in the Schwann cells of either
Cx32 knock-out or otherwise normal mice (Bone et al., 1997;
Scherer et al., 1999). Both R142W/2 and R142W/1 mice
showed age-dependent demyelination and remyelination of
peripheral nerve. In R142W/1 animals, endogenous Cx32
was no longer detectable in the myelin sheath but instead
was localized to the same intracellular compartments as the
R142W Cx32 mutant. Dominant-negative activity of intracel-
lularly retained CMTX-linked Cx32 mutants has also been
reported by Omori et al. (1996) in HeLa cell transfectants.
Taken together, these observations illustrate the potential for
certain CMTX-linked Cx32 mutants to have gain-of-function
effects and indicate that transfected PC12 cells are a suitable
system to study mutant trafficking.
Mutations in plasma membrane or secreted proteins that
inhibit transport to the cell surface can cause disease by one
of two general mechanisms (Kim and Arvan, 1998; Aridor
and Balch, 1999). Aridor and Balch (1999) have defined class
I mutations as those that prevent transport of the affected
protein to the plasma membrane but do not interfere with its
ability to be efficiently degraded. Disease results from the
absence of the wild-type protein, and any proteins associ-
ated with it, from the cell surface. In contrast, class II muta-
tions inhibit the turnover as well as the intracellular trans-
port of the affected protein. Accumulation of undegraded
protein can then induce chronic endoplasmic reticulum (ER)
stress responses, which in turn may lead to major changes in
cell physiology such as apoptosis, abnormal differentiation,
and altered proliferation. A class II-type mechanism has
been proposed for mutants of proteolipid protein that cause
Pelizaeus–Merzbacher disease (Gow and Lazzarini, 1996;
Gow et al., 1998) and of peripheral myelin protein 22 that
result in CMT type 1A (D’Urso et al., 1998; Aridor and Balch,
1999). By analogy, toxic accumulation of Cx32 (also a tetra-
spanning integral plasma membrane protein of myelin) has
been suggested as a mechanism for some CMTX-linked
Cx32 mutants (Deschenes et al., 1997), although this conten-
tion has not been experimentally addressed.
One possibility consistent with the phenotypic variation
observed in CMTX patients is that different defects in Cx32
lead to distinct transport, assembly, and degradative fates.
That differences in intracellular processing can be associated
with separate disease mechanisms is illustrated by the find-
ing that mutants of the water channel aquaporin-2 that are
restricted to the ER are linked with recessive nephrogenic
diabetes insipidus, whereas those that are arrested in the
Golgi cause a dominant form of the disease, apparently
because of formation of mixed oligomers with wild-type
aquaporin-2 (Kamsteeg et al., 1999). Given the aforemen-
tioned deleterious effects of intracellular accumulation of
undegraded mutant proteins, it is particularly important to
delineate the pathways by which mutant and wild-type
connexins are turned over. The lysosome has generally been
considered the major means of proteolysis of membrane-
associated proteins and has been shown to participate in the
turnover of gap junctional plaques (Larsen and Tung, 1978).
Recent evidence has, however, indicated that the protea-
some is involved in the degradation of many membrane-
bound and soluble proteins within the secretory pathway
(Brodsky and McCracken, 1997). This includes wild-type
connexin43 (Cx43), whose turnover rate has been reported
to be reduced by proteasomal inhibitors (Laing and Beyer,
1995). The role of the proteasome in the turnover of wild-
type (WT) Cx32 is not known, nor has the mechanism of
degradation of mutant connexins been addressed.
In the current study, we present the first integrated anal-
ysis of the intracellular transport, assembly, and degrada-
tion of CMTX-linked Cx32 mutants. We use a combination
of biochemical and morphological techniques to examine the
post-translational fate of the R142W, E186K, and E208K
CMTX-linked Cx32 mutants expressed in stable transfec-
tants of PC12 cells. Our results provide new insights into the
pathophysiology of CMTX disease as well as into the quality
control mechanisms that govern the fidelity of assembly of
connexins into gap junctional plaques.
MATERIALS AND METHODS
Cell Culture
The generation of multiple independent clonal lines of PC12J cells (a
subclone of rat pheochromocytoma cells devoid of endogenous gap
junction activity) stably expressing either wild-type human Cx32 or
J.K. VanSlyke et al
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a CMTX-linked Cx32 mutant has been described by Deschenes et al.
(1997). In brief, the coding regions of wild-type or mutant (E208K,
R142W, or E186K) Cx32 were amplified from the genomic DNA of
control subjects or CMTX patients, respectively, and subcloned into
the pREP9 expression vector for transfection; vector-only transfec-
tants served as controls. Cell lines were maintained in RPMI 1640
medium supplemented with 10% horse serum, 5% FCS, penicillin G,
streptomycin, and 400 mg/ml G418 (Deschenes et al., 1997). Expres-
sion of endogenous Cx32 in the rat hepatoma cell line MH1C1 (a
generous gift from R. Ruch, Medical College of Ohio, Toledo, OH)
was enhanced by culturing for 48 h in the presence of 10 mM
dexamethasone as previously described (Ren et al., 1994). Mouse
sarcoma cells stably transfected with the adhesion molecule liver
cell adhesion molecule (L-CAM) (S180L) (Mege et al., 1988) were
maintained in Dulbecco’s modified Eagle’s medium plus 10% FCS,
penicillin G, and streptomycin, and Chinese hamster ovary (CHO)-
K1 cells were maintained in F-12 medium containing 10% FCS.
Antibodies and Reagents
Mouse monoclonal antibody 7C6.C7 specific for Cx32 was a gener-
ous gift of E. Hertzberg (Albert Einstein College of Medicine, Bronx,
NY) and used for all immunofluorescence microscopy. For immu-
noprecipitation of Cx32, crude antiserum from rabbits immunized
with a synthetic peptide corresponding to amino acids 98–124 of rat
Cx32 (kindly provided by D. Goodenough, Harvard Medical
School, Boston, MA; Goodenough et al., 1988) was used in pulse–
chase experiments, whereas affinity-purified polyclonal rabbit anti-
Cx32 immunoglobulin G (IgG) purchased from Zymed (San Fran-
cisco, CA; 71-0600) was used for cross-linking analysis. Cx43 was
immunoprecipitated with affinity-purified polyclonal rabbit anti-
Cx43 antibodies prepared as previously described (Musil et al.,
1990), and L-CAM was immunoprecipitated with a polyclonal rab-
bit antiserum kindly provided by W. Gallin (University of Alberta,
Edmonton, Alberta, Canada). Marker proteins for the ER (calreticu-
lin) and Golgi stack (mannosidase II) were immunodetected using
monospecific polyclonal rabbit antisera from Affinity BioReagents
(Golden, CO; PA3-900) and K. Moreman (University of Georgia,
Athens, GA), respectively. FITC-conjugated donkey anti-mouse IgG
(Jackson ImmunoResearch, West Grove, PA) and rhoda-
mine-conjugated goat anti-rabbit IgG (Pierce, Rockford, IL) were
used as secondary antibodies.
Unless otherwise noted, all reagents were from Sigma (St. Louis,
MO). Stock solutions of proteasomal inhibitors were prepared in
DMSO at the following concentrations and stored at 220°C: 26 mM
N-acetyl-leu-leu-norleucinal (ALLN), 1 mM lactacystin, and 5 mM
carboxybenzyl-leucyl-leucyl-leucyl-vinylsulphone (ZL3VS). ZL3VS
was a kind gift from M. Bogyo (Harvard Medical School). A con-
centrated stock of chloroquine (10 mM) was freshly prepared in
double-distilled H2O (ddH2O) for each experiment. Other reagents
were stored as concentrated stocks at 20°C: leupeptin (10 mg/ml in
ddH2O), cycloheximide (2 mg/ml in ddH2O), and brefeldin A (BFA;
Epicentre, Madison WI; 5 mg/ml in ethanol). Final concentrations in
experiments were as follows: 100 mM ALLN, 10 mM lactacystin, 20
mM ZL3VS, 100 mg/ml leupeptin, 20 mg/ml cycloheximide, 200 mM
chloroquine, and 6 mg/ml BFA.
Immunofluorescence Microscopy
Glass coverslips in 96-well dishes were treated with a solution of 0.5
mg/ml poly-d-lysine (Sigma; P7886) in 0.15 M boric acid, pH 8.4 for
$30 min at 37°C and rinsed twice with PBS without Ca21 and Mg21.
PC12 transfectants were plated onto the coated coverslips and used
for experiments after 4 d of culture, when ;75% confluent. For
experiments at 37°C, the plating medium was replaced with fresh
culture medium (with or without additions). Incubations at 20°C
were conducted in Leibovitz’s L15 medium (Life Technologies,
Gaithersburg, MD; 11415-023) supplemented with 10% horse serum,
5% FCS, penicillin G, and streptomycin, in an ambient air (no CO2)
refrigerator maintained at 20°C with a heating unit in a cold room
as described in VanSlyke and Musil (2000).
At the time points specified in the figure legends, cells were
rinsed three times with cold PBS (with Ca21 and Mg21) before fixing
with prechilled 2% paraformaldehyde in PBS for 30 min at room
temperature. After fixation, cells were washed and then incubated
in PBS for at least 30 min. Coverslips were incubated 30–60 min in
blocking buffer (PBS plus 0.5% normal goat serum, 0.1% BSA, 0.2%
Triton X-100, and 0.02% sodium azide) before addition of the de-
sired primary antibody (or, in the case of double labeling, antibod-
ies) diluted in blocking buffer. Hybridoma supernatant containing
7C6.C7 anti-Cx32 antibodies was used diluted 1:1. After an over-
night incubation at 4°C in a humidified chamber, cells were incu-
bated for 30 min in blocking buffer and then incubated with the
appropriate secondary antibody for 1.5 h at room temperature
followed by another 30-min rinse in blocking buffer. The coverslips
were mounted onto glass slides with MOWIOL 4–88 mounting
medium (Calbiochem, La Jolla, CA), and immunofluorescence im-
ages were captured using a Leica (Nussloch, Germany) DM LD
photomicrography system and Scion (Frederick, MD) Image 1.60
software.
Metabolic Labeling
For metabolic labeling at 37°C, cells were first starved for methio-
nine for 30 min at 37°C in Dulbecco’s modified Eagle’s medium
lacking methionine supplemented with 5% dialyzed FCS and 2 mM
glutamine (“labeling” medium). The medium was then replaced
with fresh labeling medium containing [35S]methionine
(EXPRE35S35S; New England Nuclear, Boston, MA; 0.3 mCi/60-mm
dish of cells, scaled proportionally for dishes of other sizes). For
pulse–chase analysis, the radioactive medium was removed after a
30-min pulse and the cultures were rinsed once before addition of
fresh complete culture medium supplemented with 0.5 mM nonla-
beled methionine. For metabolic labeling at 20°C for analysis of
Triton X-100 solubility (see Figure 3), cells in 60-mm dishes were
incubated in 2.5 ml of reduced bicarbonate labeling medium (Earle’s
minimal essential medium lacking methionine and containing 15
mM HEPES, 0.35 g/l bicarbonate, 2 mM glutamine, and 5% dia-
lyzed FCS) containing 0.3 mCi of [35S]methionine at 37°C under
ambient CO2 conditions. For analysis of connexon assembly at 20°C
(see Figure 8), cells in 60-mm dishes were first incubated in 2.5 ml of
reduced bicarbonate labeling medium for 30 min at 37°C under
ambient CO2 conditions. The medium was replaced with 2.5 ml of
fresh reduced bicarbonate labeling medium containing 0.3 mCi of
[35S]methionine, and the cells were incubated at 37°C for 20 min
under the same conditions before chilling the tissue culture dish
briefly to 4°C and continuing the labeling for an additional 4 h 40
min in a 20°C ambient CO2 incubator (VanSlyke and Musil, 2000).
The initial 20 min of labeling at 37°C increases the amount of
radiolabeled connexin synthesized but is too short to permit detect-
able assembly of wild-type Cx32 into Triton X-100-insoluble gap
junctional plaques.
Immunoprecipitation
With the exception of cells to be lysed under nondenaturing condi-
tions in Triton X-100 (see below), cells were rinsed once with PBS at
4°C and resuspended in lysis buffer (5 mM Tris base, 5 mM EDTA,
5 mM EGTA, 10 mM iodoacetamide, and 2 mM PMSF, pH 8.0)
supplemented with 0.6% SDS, 250 mg/ml soybean trypsin inhibitor,
and 200 mM leupeptin. The lysates were then immunoprecipitated
with the desired antibody as described by Le and Musil (1998). Two
modifications were made for immunoprecipitation of Cx32: first,
cells were lysed in SDS at room temperature for 30 min instead of at
100°C for 3 min to minimize aggregation of Cx32; and second,
samples were precleared with protein A-Sepharose for 2 h at 4°C
before addition of anti-Cx32 antibody (VanSlyke and Musil, 2000).
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Triton X-100 Solubilization and Chemical Cross-
Linking
Metabolically labeled tissue culture cells were resuspended in incu-
bation buffer (136.8 mM NaCl, 5.36 mM KCl, 0.336 mM Na2HPO4,
0.345 mM KH2PO4, 0.8 mM MgSO4, 2.7 mM CaCl2, and 20 mM
HEPES, pH 7.5) and solubilized in the presence of 1% Triton X-100
on ice for 30 min as previously described (Musil and Goodenough,
1993). The cell extract was separated into Triton X-100-insoluble and
-soluble fractions by centrifugation at 100,000 3 g (45,000 rpm in a
TLA100.3 tabletop ultracentrifuge; Beckman Instruments, Palo Alto,
CA) for 50 min at 4°C. For analysis of Cx32 Triton X-100 solubility
(see Figure 3), each fraction was lysed in SDS and immunoprecipi-
tated as described for Cx43 (Musil and Goodenough, 1991), except
that the samples were lysed in SDS at room temperature for 30 min
and precleared with protein A-Sepharose as described above. For
cross-linking analysis of Cx32 connexons, the Triton X-100-soluble
fraction was incubated for 30 min on ice with 1 mM ethylene
glycolbis(succinimdylsuccinate) (EGS; Pierce), freshly diluted from
a 100 mM stock in DMSO. The cross-linking reaction was stopped
by addition of glycine as detailed by Musil and Goodenough (1993),
SDS was added to a final concentration of 0.6%, and the sample was
incubated for 30 min at room temperature before immunoprecipi-
tation of Cx32 as described above. Mock cross-linked control sam-
ples were treated identically but received DMSO only.
SDS-PAGE and Quantification
Monomeric Cx32, Cx43, and L-CAM immunoprecipitates were an-
alyzed on 11, 10, or 7.5% SDS-PAGE gels, respectively, after incu-
bation of samples in SDS-PAGE sample loading buffer for either 30
min at room temperature (Cx32) or for 3 min at 100°C (Cx43 and
L-CAM). Samples containing cross-linked Cx32 were warmed to
37°C for 5 min before analysis on 7.5–12.5% gradient gels. The dried
gels were quantitated on a 445 SI PhosphorImager (Molecular Dy-
namics, Sunnyvale, CA) using IPLab Gel software (Signal Analytics,
Vienna, VA).
RESULTS
Intracellular Localization of the R142W, E186K, and
E208K CMTX-linked Cx32 Mutants in PC12 Cell
Transfectants
We examined three CMTX-linked Cx32 point mutants re-
ported by Deschenes et al. (1997) to be associated with mod-
erate to severe clinical disease. The R142W mutation con-
verts arginine 142 to a tryptophan in a position within the
third transmembrane domain of Cx32 that is occupied by a
basic residue in all known members of the connexin family
and that is thought to contribute to the gap junction channel
pore. The E186K mutation changes the charge of an amino
acid at the end of the second extracellular loop that is
perfectly conserved within the connexin family, whereas the
E208K mutation similarly reverses the polarity of another
perfectly conserved glutamic acid residue that borders the
last transmembrane domain. These mutants have been re-
ported to be nonfunctional when expressed in paired Xeno-
pus oocytes (Bruzzone et al., 1994; Castro et al., 1999).
Figure 1 shows the steady-state localization of these mu-
tants and WT Cx32 when stably expressed in otherwise
connexin-deficient PC12 transfectants. WT Cx32 accumu-
lated on the cell surface and concentrated at cell–cell inter-
faces in the punctate distribution characteristic of gap junc-
tional plaques (Figure 1A; also see Figure 5A). As previously
reported (Deschenes et al., 1997), the R142W, E186K, and
E208K Cx32 mutants instead were localized by immunoflu-
orescence microscopy exclusively intracellularly in multiple
independent clones (Figure 1; also see Figure 5). They were
also undetectable on the plasma membrane by cell surface
biotinylation (our unpublished data). Accumulation of im-
munodetectable E208K, R142W, or E186K Cx32 on the cell
surface could not be induced by incubating the cells for 48 h
at either 25 or 27°C (our unpublished data). The trafficking
defect of these mutants is therefore distinct from that of the
DF508 form of the cystic fibrosis transmembrane conduc-
tance regulator (CFTR), which is retained within the ER at
37°C but is transported to the cell surface at lower temper-
atures (Denning et al., 1992).
Double-staining immunofluorescence microscopy studies
revealed differences in the subcellular localization of the
CMTX-linked Cx32 mutants. E208K Cx32 showed nearly
perfect colocalization with an ER marker (calreticulin) in a
distribution readily distinguishable from that obtained with
a Golgi resident (mannosidase II) (Figure 1). In each of the
E208K Cx32-expressing PC12 clonal cell lines we have ex-
amined, the perinuclear, Golgi-like staining pattern de-
scribed by Deschenes et al. (1997) in a minority of highly
expressing cells was not observed. Possibly, such transfec-
Figure 1. Steady-state intracellular localization of WT Cx32 and
CMTX-linked Cx32 mutants. PC12 cell lines expressing WT Cx32
(A), R142W Cx32 (C and D), E186K Cx32 (E and F), or E208K Cx32
(G and H) or transfected with vector only (B) were fixed and
immunostained with anti-Cx32 antibodies (A, C, E, and G). Cells
expressing CMTX-linked Cx32 mutants were doubly immuno-
stained for markers specific for either the cis/medial-Golgi (manno-
sidase II; D and F) or the ER (calreticulin; H). Arrows (C–F) point to
Golgi regions doubly stained for Cx32 and mannosidase II.
J.K. VanSlyke et al
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tants were selected out of the population during repeated
passage. The intracellular localization of E208K Cx32 was
unaffected by treatments that accumulate newly synthe-
sized, transport-competent secretory proteins within either
the peripheral elements of the intermediate compartment or
the Golgi apparatus (16°C, nocodazole; 20°C, monensin)
(Matlin and Simons, 1983; Hsu et al., 1991; Jackson et al.,
1993; our unpublished results). The E186K and R142W Cx32
mutants could also be detected within the ER. In contrast to
E208K Cx32, however, their staining pattern was not re-
stricted to this organelle but instead included Golgi-like
perinuclear compartments where they colocalized with
mannosidase II. These findings suggest that E208K Cx32
remains confined to the ER, whereas the R142W and E186K
mutants are competent to traffic to more distal compart-
ments of the secretory pathway but not to the cell surface.
Rapid Turnover of WT and Mutant Cx32 in
PC12 Cells
As defined by Aridor and Balch (1999), class II mutations
are distinguished from class I defects in that they inhibit
not only the intracellular transport but also the degrada-
tion of the affected protein, leading to deleterious overac-
cumulation within the early secretory pathway. Reduced
turnover of disease-causing mutants of both soluble and
integral plasma membrane proteins has been recapitu-
lated in tissue culture cell systems (Graham et al., 1990;
Sadeghi et al., 1997; Skovronsky et al., 1998). In some (but
not all) cases, both the trafficking and degradation defects
of class II mutants are associated with polymerization of
the affected protein in aggregates insoluble in the non-
ionic detergent Triton X-100 (Graham et al., 1990; Kim and
Arvan, 1998; Skovronsky et al., 1998). To investigate
whether the E208K, R142W, and E186K Cx32 mutants
behave like class I or class II mutants in PC12 transfec-
tants, we examined their rate of turnover (Figure 2) and
detergent sensitivity (Figure 3). Less than 30% of WT Cx32
metabolically labeled with [35S]methionine during a 30-
min pulse was immunoprecipitable after a 4-h chase, as
expected from the rapid rate of degradation typical of
Cx32 and other members of the connexin family in cul-
tured cells as well as in vivo (Fallon and Goodenough,
1981; Musil et al., 1990; Beardslee et al., 1998). As assessed
by pulse– chase analysis, each of the three CMTX-linked
Cx32 mutants tested was degraded at least as rapidly as
the wild-type protein (Figure 2), whereas a [35S]methi-
onine-labeled, metabolically stable cellular protein (actin)
was not detectably turned over during the same period
(our unpublished data). To assess the detergent solubility
of WT and mutant forms of Cx32, PC12 transfectants
labeled for 4 h with [35S]methionine were lysed in 1.0%
Triton X-100 at 4°C (Figure 3). Previous studies have
demonstrated that newly synthesized WT Cx43 is soluble
under these conditions and acquires resistance to Triton
X-100 only upon incorporation into gap junctional
plaques (Musil and Goodenough, 1991). We show here
that WT Cx32 has similar properties. [35S]methionine-
labeled Cx32 endogenously expressed in MH1C1 hepa-
toma cells was essentially completely (.96%) Triton sol-
uble when metabolically labeled at 20°C, a temperature at
which transport to the plasma membrane and therefore
formation of gap junctional plaques are inhibited (Matlin
and Simons, 1983). In contrast, a considerable amount
(45%) of [35S]methionine-labeled Cx32 synthesized at
37°C was insensitive to Triton X-100. Given the well-
known insolubility of Cx32 gap junctional plaques in most
nonionic detergents (Hertzberg, 1984), the acquisition of
Triton X-100 resistance of Cx32 in MH1C1 cells at 37°C is
likely to be due to gap junction assembly. WT Cx32 ex-
pressed in PC12 cells showed a comparable temperature
dependence in its response to Triton X-100, in keeping
with their ability to form gap junctional plaques. In con-
trast, each of the three CMTX-linked Cx32 mutants exam-
ined could be almost completely (.95%) solubilized by
Triton X-100 when synthesized at 37°C. Examination of
the total cellular pool of mutant Cx32 by Western blotting
also failed to provide evidence of accumulation in stable
high-molecular-weight aggregates (our unpublished re-
sults). The R142W, E186K, and E208K forms of Cx32 there-
fore behave differently than the PiZ mutant of a1-anti-
trypsin, of which a fraction too small to be detectable by
short-term metabolic labeling slowly accumulates in deg-
radation-resistant, Triton X-100-insoluble aggregates that
over time become the predominant cellular form of the
protein as assessed by immunoblotting (Graham et al.,
1990).
Figure 2. Pulse–chase analysis of the turnover of WT Cx32 and
CMTX-linked mutants. PC12 transfectants were metabolically la-
beled with [35S]methionine for 30 min at 37°C and then chased in the
presence of excess cold methionine for 0, 2, or 4 h. Cx32 was
immunoprecipitated from equal volumes of total cell lysate (and
therefore from equal numbers of cell equivalents) and analyzed by
SDS-PAGE. The amount of [35S]methionine-Cx32 recovered by im-
munoprecipitation after each chase period was expressed as a per-
centage of [35S]methionine-Cx32 immunoprecipitable immediately
after the pulse.
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Pathways of WT Cx32 Degradation
The rapidity with which both WT and mutant forms of Cx32
are turned over despite their disparate subcellular localiza-
tions raised the question of whether they were degraded by
the same or distinct mechanisms. To examine this issue, we
treated PC12 cell transfectants with inhibitors of either the
lysosome or the proteasome, the two major pathways impli-
cated in the destruction of integral plasma membrane pro-
teins (Seglen, 1983; Lee and Goldberg, 1998).
We first investigated the mechanism(s) by which WT Cx32
is degraded by pulse–chase analysis (Figure 4). To inhibit
lysosomal degradation, we used the tripeptide leupeptin
instead of a weak base to avoid the potentially confounding
effect of the latter on Golgi intracisternal pH and function
(Seglen, 1983; Stevens and Forgac, 1997). Addition of leu-
peptin to the chase medium modestly but reproducibly in-
creased the amount of pulse-labeled Cx32 that survived a
6-h chase by ;1.5-fold. A much greater inhibition of degra-
dation was achieved in the presence of the proteasome
inhibitor ALLN (Figure 4). In a more limited series of exper-
iments, a mechanistically distinct, highly selective blocker of
the proteasome (ZL3VS) had a comparable effect, increasing
the amount of pulse-labeled [35S]methionine-WT Cx32 that
survived a 6-h chase an average of 2.3-fold (60.35; n53). The
relative efficacy of proteasomal and lysosomal inhibitors in
slowing WT Cx32 turnover is very similar to that previously
reported by Laing and Beyer (1995) for WT Cx43 endog-
enously expressed in a CHO cell subclone.
The role of lysosomes in the turnover of at least a fraction
of WT Cx32 molecules was corroborated by immunofluores-
cence microscopy (Figure 5). Unlike leupeptin, weak bases
such as chloroquine inactivate proteases within endosomes
and lysosomes by neutralizing lumenal pH. A consequence
of this activity is osmotic swelling of these compartments
into characteristic “doughnut” structures that are morpho-
logically distinct from the Golgi and other normally acidic
organelles (Mellman et al., 1986). WT Cx32 could be readily
detected in such distended vesicles after a 3- to 6-h incuba-
tion of cells with 200 mM chloroquine (Figure 5C). In con-
trast, proteasome inhibitors including ALLN (Figure 5B) and
ZL3VS (our unpublished results) did not detectably change
the pattern of WT Cx32 staining.
Proteasome inhibitor-sensitive degradation of integral
plasma membrane proteins has been reported to occur be-
fore their exit from the ER and/or after their transport to the
cell surface (reviewed by Bonifacino and Weissman, 1998).
Although evidence that WT Cx43 may be subjected to pro-
teasomal degradation at the latter site has been reported by
Laing et al. (1997), it is unknown whether this process is also
involved in connexin turnover at earlier stages of the secre-
tory pathway. Connexins are not glycosylated or known to
undergo any other type of post-translational modification
that could be used to biochemically monitor their transport
through the cell. The extent of proteasome inhibitor-sensi-
tive turnover of WT Cx32 in the ER was therefore assessed
by conducting pulse–chase experiments in the presence of
BFA, which blocks the vesicular export of newly synthesized
proteins from this compartment (Klausner et al., 1992) (Fig-
Figure 3. Solubility of WT Cx32 and CMTX-linked mutants in
Triton X-100. Cx32-expressing cells were metabolically labeled with
[35S]methionine for either 4 h at 37°C or 5 h at 20°C. Cells were lysed
in 1% Triton X-100 at 4°C and subjected to centrifugation at
100,000 3 g for 50 min. Cx32 was immunoprecipitated from the total
extract (T), Triton X-100-soluble supernatant (S), and Triton X-100-
insoluble pellet (P) and analyzed by SDS-PAGE. In all cases, recov-
ery of radiolabeled Cx32 (S 1 P/T) was $93%. N.D., not deter-
mined.
Figure 4. Pulse–chase analysis of degradation of WT Cx32 and
CMTX-linked Cx32 mutants. PC12 cell transfectants were metabol-
ically labeled for 30 min with [35S]methionine and then chased at
37°C for 6 h in either the absence or presence of 100 mM ALLN or
100 mg/ml leupeptin. Cx32 was immunoprecipitated from equal
volumes of total cell lysate (and therefore from equal numbers of
cell equivalents) and analyzed by SDS-PAGE. The data are pre-
sented as the fold increase in the percent recovery of Cx32 after a 6-h
chase in the presence of inhibitors relative to the percent recovery of
Cx32 in the absence of inhibitors.
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ure 6). To examine only the initial stages of connexin deg-
radation, and because connexins might become subject to
additional, physiologically irrelevant proteolytic pathways
during prolonged exposure to BFA, we labeled cells for only
30 min and limited our analysis to a 2- to 3-h chase. During
this period, BFA did not slow the degradation of WT Cx32 in
PC12 cell transfectants. Turnover of WT Cx32 in either the
absence or presence of BFA was efficiently inhibited by
the proteasome inhibitor ALLN. BFA also had very little
effect on the degradation of endogenously expressed WT
Cx32 in MH1C1 cells or WT Cx43 in CHO, normal rat
kidney, L929, or primary lens epithelial cells (CHO data
shown in Figure 6). In all cell types examined, general
ER–Golgi trafficking was sensitive to BFA as verified by
redistribution of mannosidase II into the ER (our unpub-
lished results). Rapid, proteasome-mediated degradation
in the ER is therefore not limited to a single connexin
species or an artifact of exogenous connexin expression.
Control experiments demonstrated that BFA strongly in-
hibited the otherwise rapid (t1/2 ;3 h) degradation of the
connexin-unrelated integral plasma membrane protein L-
CAM (Figure 6), demonstrating that ER degradation is not
a general consequence of BFA treatment but instead re-
flects a specific property of connexins.
Pathways of Mutant Cx32 Degradation
Having examined the role of the lysosome and proteasome in
WT Cx32 turnover, we next investigated the involvement of
these pathways in the degradation of the E208K, R142W, and
E186K CMTX-linked Cx32 forms. Pulse–chase analysis re-
vealed that all three mutants were as sensitive to the protea-
some inhibitor ALLN as the wild-type protein (Figure 4). The
lysosomal inhibitor leupeptin enhanced the recovery of the
R142W mutant to about the same extent as it did WT Cx32 but
did not influence the turnover of E208K Cx32, in keeping with
the exclusively ER immunolocalization pattern of the latter
mutant at steady state (Figure 1). Surprisingly, leupeptin also
had no detectable effect on the turnover of the E186K Cx32
mutant despite its ability to traffic to post-ER compartments.
Participation of the lysosome in the degradation of R142W
Cx32, but not of the E186K or E208K mutants, was sup-
ported by immunolocalization studies (Figure 5). Similar to
its effect on WT Cx32, chloroquine treatment of R142W
Cx32-expressing cells caused some of the mutant molecules
to accumulate in swollen vesicles with the characteristic
doughnut-like morphology taken on by components of the
endosome–lysosome system in the presence of this lysoso-
motropic amine (Figure 5F). In contrast, neither the E186K
Figure 5. Effect of lysosomal and proteasomal inhibitors on WT and mutant Cx32 immunostaining. PC12 cell transfectants expressing WT Cx32
(A–C), R142W Cx32 (D–G), E186K Cx32 (H–K), or E208K Cx32 (L–N) were stained for Cx32 after incubation for 6 h at 37°C with medium alone
(A, D, H, and L), 100 mM ALLN (B, E, I, and M), 200 mM chloroquine (C, F, J, and N), or 100 mg/ml leupeptin (G and K). Insets in G and K, cells
were chased with 20 mg/ml cycloheximide in the presence of 100 mg/ml leupeptin for 3.5 h at 37°C.
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(Figure 5J) nor the E208K (Figure 5N) Cx32 mutant was
detected in such distended vesicles after chloroquine expo-
sure. R142W Cx32 (Figure 5G), but not the E186K species
(Figure 5K), could also be observed in lysosome-like punc-
tate structures after treatment of cells with leupeptin. Be-
cause leupeptin does not cause vacuolar swelling, staining
of R142W Cx32 in the endosome–lysosome system was often
not obvious above anti-Cx32 immunoreactivity in the ER but
became readily detectable if cycloheximide was used to
chase preexisting Cx32 into post-ER compartments (Figure
5G, inset). The proteasome inhibitor ALLN increased the
intensity but did not change the pattern of staining of the
R142W, E186K, or E208K Cx32 species (Figure 5, E, I, and
M). The transport defects of these mutants therefore cannot
be overcome by reducing their proteasomal turnover.
Although successfully used to assess the role of the pro-
teasome in the turnover of a wide variety of proteins, ALLN
also inhibits certain lysosomal cathepsins as well as calpains
(Lee and Goldberg, 1998). To rule out the possibility that the
effect of ALLN on the degradation of the Cx32 mutants was
due to nonproteasomal activity of the drug, we conducted
immunocytochemical studies using the protein synthesis
blocker cycloheximide. Control experiments demonstrated
that 20 mg/ml cycloheximide effectively inhibited incorpo-
ration of [35S]methionine into nascent proteins within 10 min
and did not alter the rate of degradation of previously
synthesized [35S]methionine-labeled E208K Cx32, R142W
Cx32, or E186K Cx32 (our unpublished results). Incubation
of cells expressing these mutants with cycloheximide for 6 h
resulted in the almost complete loss of anti-Cx32 immuno-
reactivity, in keeping with their rapid rate of degradation.
As expected from pulse–chase analysis (Figure 4), the dis-
appearance of mutant staining in cycloheximide-treated
cells was largely prevented by ALLN (data for E208K Cx32
shown in Figure 7 and for E186K Cx32 in Figure 8). Similar
results were obtained with the related proteasome inhibitor
Cbz-leu-leu-leucinal as well as with two highly selective,
mechanistically distinct blockers of proteasomal proteolysis,
ZL3VS and lactacystin (data for E208K Cx32 shown in Figure
7). The specificity of this effect for proteasomal inhibitors
was demonstrated using the E208K Cx32 mutant, which in
pulse–chase experiments was shown to be insensitive to
leupeptin (Figure 4). Neither leupeptin (Figure 7G) nor the
mechanistically unrelated lysosomal inhibitor chloroquine
(Figure 7H) was able to prevent the loss of immunologically
Figure 6. Degradation of wild-type connexins retained within the
ER. WT Cx32-expressing PC12 cell transfectants, CHO cells endog-
enously expressing WT Cx43, and L-CAM-expressing S180L cells
were pulse-labeled for 30 min with [35S]methionine in the absence
or presence of 6 mg/ml BFA. Cells were then chased (with or
without BFA) for 2, 3, or 6 h, respectively. BFA causes retention of
newly synthesized proteins within the ER. Where indicated, 100 mM
ALLN was included in the chase medium. The data are presented as
the fold increase in the percent recovery of pulse-labeled protein
(Cx32, Cx43, or L-CAM) after the chase period in the presence of
inhibitor(s) relative to the percent recovery of pulse-labeled protein
in the absence of inhibitor. Recovery after chase in the absence of
inhibitors (control) averaged 56% for WT Cx32 and 60% for WT
Cx43. Complete inhibition of Cx degradation (5100% recovery)
therefore corresponds to a 1.8-fold increase in recovery of WT Cx32
and a 1.7-fold increase in recovery of WT Cx43, very close to the
values obtained in the presence of ALLN either with or without
BFA. For each experimental condition, n 5 3.
Figure 7. Effect of lysosomal and proteasomal inhibitors on E208K
Cx32 degradation. E208K Cx32-expressing cells were incubated for 6 h
at 37°C in either the absence (A) or presence (B–I) of 20 mg/ml cyclo-
heximide with the following additions: 100 mM ALLN (C), 20 mM
Cbz-leu-leu-leucinal (D), 10 mM lactacystin (E), 20 mM ZL3VS (F), 100
mg/ml leupeptin (G), 200 mM chloroquine (H), or 100 mM ALLM (I).
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detectable E208K Cx32 in cycloheximide-treated cells. Fur-
thermore, ALLM, closely related to ALLN and an effective
blocker of calpains and cathepsins but not of the proteasome
(Rock et al., 1994), had a much weaker effect on E208K Cx32
recovery than did ALLN, lactacystin, or ZL3VS (Figure 7I).
Although comparable experiments were not possible with
WT Cx32 because of the fact that cycloheximide itself
strongly inhibits degradation of wild-type forms of both
Cx32 and Cx43 (L.S. Musil, unpublished results), the afore-
mentioned ability of ZL3VS to reduce WT Cx32 turnover in
pulse–chase experiments strongly supports a role for the
proteasome in the turnover of this species as well.
E186K Cx32 Undergoes Retrograde Transport Back
to the ER
Proteasome-mediated degradation in the early secretory
pathway requires that the substrate protein, in either an
intact or partially degraded state, be extracted from mem-
branes and inserted into cytosolic proteasomes (reviewed by
Plemper and Wolf, 1999). To date, the ER is the only intra-
cellular site at which this “dislocation” process has been
reported to occur. Given that E186K Cx32 does not enter the
endosome–lysosome system or traffic to the cell surface, the
question arises of how this mutant is degraded from post-ER
compartments. To address this issue, we took advantage of
the serendipitous observation that a 3-h incubation of living
cells at 20°C caused E186K Cx32 to concentrate very strongly
within the Golgi region (Figure 8A). To study the fate of this
post-ER pool of E186K Cx32, we returned cells to 37°C in the
presence of cycloheximide to inhibit new protein synthesis.
Beginning at ;10 min after warm-up, the perinuclear stain-
ing pattern of the mutant was gradually replaced by a more
diffuse, reticular distribution that was most striking 30–50
min later (Figure 8, C and E). Double-staining immunoflu-
orescence microscopy demonstrated that the mutant now
colocalized predominantly with the ER marker calreticulin
(Figure 8F) instead of with mannosidase II (Figure 8D),
indicating that it had undergone retrograde transport back
into the ER. This interpretation is in keeping with previous
data suggesting that Golgi-to-ER transport is inhibited to a
greater extent at 20°C than anterograde ER-to-Golgi move-
ment, leading to a relative accumulation of transport-com-
petent proteins in the Golgi at 20°C that is reversed upon
return to 37°C (Hsu et al., 1991; Cole et al., 1996). Immuno-
detectable E186K Cx32 disappeared over the next 5 h (Figure
8G), as expected from its rapid rate of turnover in either the
absence (Figure 2) or presence (our unpublished results) of
cycloheximide as determined by pulse–chase analysis. Deg-
radation of E186K Cx32 over the same period, but not its
retrograde transport to the ER, was blocked by the protea-
some inhibitor ALLN (Figure 8I). Taken together with the
data in Figures 4 and 5, these results indicate that E186K
Cx32 is turned over by a proteasome-mediated pathway
even after its initial exit from the ER. Degradation of such
post-ER pools of E186K Cx32 may require retrieval back into
the endoplasmic reticulum, from which it might access the
proteasome via the translocon channel.
Effect of CMTX-linked Cx32 Mutations on
Connexon Assembly
The first step in gap junction formation is the noncovalent
assembly of six connexin monomers into a connexon before
transport to the cell surface. It has been suggested that the
ability of intracellularly retained CMTX-linked Cx32 mu-
tants to act as dominant negative inhibitors of WT connexins
is due to the formation of mixed connexons (Omori et al.,
1996; Deschenes et al., 1997). To assess the competence of the
R142W, E186K, and E208K Cx32 mutants to undergo con-
nexon assembly, we assayed their oligomerization state
Figure 8. Retrograde transport of E186K Cx32. E186K Cx32-ex-
pressing PC12 cell transfectants were incubated at 20°C for 3 h and
then either fixed immediately (A and B) or shifted to 37°C in the
presence of 20 mg/ml cycloheximide. The latter cells were incubated
at 37°C for either 1 h (C–F) or 6 h (G and H) in the absence of further
additions or for 6 h in the presence of 100 mM ALLN (I and J). All
cells were immunostained for Cx32 and in some cases doubly
stained for the cis/medial-Golgi (mannosidase II; B, D, H, and J) or
the ER (calreticulin; F). Arrows in C and D point to regions that stain
for Cx32 but not mannosidase II; arrows in E and F indicate areas of
colocalization of Cx32 and calreticulin.
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when expressed individually in PC12 cell transfectants (Fig-
ure 9). We first verified that assembly of WT Cx32 into
connexons could be detected using techniques previously
established for Cx43 (Musil and Goodenough, 1993). Cells
were metabolically labeled with [35S]methionine and then
lysed in the presence of Triton X-100 at 4°C before cross-
linking of the soluble fraction with EGS and analysis of Cx32
oligomers by immunoprecipitation and SDS-PAGE. As ex-
pected, WT Cx32 in PC12 transfectants could be cross-linked
to an ;150-kDa species indistinguishable from Cx32-con-
taining connexons isolated from MH1C1 cells (Figure 9, lanes
2 and 4) or rat liver (our unpublished results; Cascio et al.,
1995). In contrast, none of the three mutants could be cross-
linked into a detectable connexon species (Figure 9, lanes 6,
8, and 10) despite expression levels roughly equivalent to
(E186K and R142W) or somewhat greater than (E208K) that
of WT Cx32. Similar results were obtained if cells were
labeled at 37°C in the presence of ALLN to reduce the rate of
connexin degradation (our unpublished results), indicating
that rapid turnover is not responsible for the inability of the
mutants to assemble into connexons.
DISCUSSION
Although defects in the Cx32 gene were identified as the
cause of CMTX disease more than 7 years ago (Bergoffen et
al., 1993), the mechanism(s) by which these mutations lead
to peripheral nerve pathology have not been deliniated. In
this study we have examined the assembly, trafficking, and
degradation of three CMTX-linked Cx32 point mutants sta-
bly expressed in PC12 cell transfectants. The E208K, R142W,
and E186K Cx32 mutants were undetectable on the cell
surface by either morphological (immunofluorescence mi-
croscopy) or biochemical (cell surface biotinylation) assays.
Insofar as oligomeric assembly is a general prerequisite for
the trafficking of multisubunit proteins to the cell surface
(Hammond and Helenius, 1995), the inability of these mu-
tants to form connexons is also consistent with their intra-
cellular retention. Two major conclusions arise from our
findings and are discussed below. First, the E208K, R142W,
and E186K Cx32 mutations are unlikely to cause CMTX by
accumulating in poorly degradable intracellular aggregates.
Second, each of these mutants has a distinct intracellular
trafficking and degradative fate, revealing a multistep qual-
ity control mechanism that prevents abnormal connexins
from being transported to the plasma membrane.
Implications for the Mechanism of CMTX Disease
By definition, mutations that prevent the transport of a
plasma membrane protein to the cell surface cause the loss
of the protein’s wild-type function. As described by Aridor
and Balch (1999), class I mutations result in the efficient
degradation of the affected secretory protein at the level of
the ER by a proteasome-mediated process. Class II muta-
tions inhibit the protein’s turnover as well as its intracellular
transport, resulting in chronic, pathological activation of ER
stress responses and in some cases misfolding of the accu-
mulated mutant protein into Triton X-100-insoluble aggre-
gates (Kim and Arvan, 1998; Aridor and Balch, 1999). Three
lines of evidence indicate that the E208K, R142W, and E186K
CMTX-linked forms of Cx32 behave as class I instead of class
II mutants in PC12 cell transfectants. First, pulse–chase anal-
ysis revealed that all three mutants, like wild-type connex-
ins, were degraded at a rapid rate (Figure 2). Inhibition of
new protein synthesis with cycloheximide resulted in the
loss of all immunofluorescently detectable E186K Cx32 (Fig-
ure 8) as well as E208K (Figure 7) and R142W Cx32 (our
unpublished results) within a 6-h period, indicating that fast
turnover is a property of the total cellular pool of mutant
Cx32 and not just the fraction that incorporates [35S]methi-
onine during a 30-min pulse. Second, ALLN and lactacystin
inhibited the degradation of all three mutants within the
early secretory pathway, implicating the proteasome in their
destruction. Third, the mutants were soluble in 4°C Triton
X-100 as detected by either immunoprecipitation after a 4-h
labeling (.twice the t1/2 of the protein) (Figure 3) or by
Western blotting (our unpublished results), in contrast to
certain abnormal proteins that form toxic aggregates (Gra-
ham et al., 1990; Skovronsky et al., 1998; Greenfield et al.,
Figure 9. CMTX-linked Cx32
mutants do not assemble connex-
ons. PC12 cells expressing WT
Cx32 (lanes 3 and 4), mutant Cx32
(lanes 5–10), or no Cx32 (lanes 11
and 12) were metabolically la-
beled for 20 min at 37°C and then
4.6 h at 20°C as described in MA-
TERIALS AND METHODS. Alter-
natively, MH1C1 cells (lanes 1 and
2) were labeled for 4 h at 37°C.
Triton X-100-solubilized cell ex-
tracts were cross-linked with 1
mM EGS for 30 min at 4°C (lanes
2, 4, 6, 8, 10, and 12), or treated
with DMSO only for a mock–
cross-linked control (lanes 1, 3, 5,
7, 9, and 11). Cx32 was immuno-
precipitated and analyzed by
SDS-PAGE on 7.5–12.5% gradient
gels. The positions of monomeric Cx32 (m) and cross-linked Cx32 connexons (cxon) are indicated at the left. The bands migrating slower
than monomeric Cx32 in non– cross-linked mutant immunoprecipitates are mainly SDS-induced aggregates of Cx32.
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1999). Our findings in PC12 cells are consistant with the
observation (L. Bone, A. Messing, R. Balice-Gordon, K. Fis-
chbeck, and S. Scherer, unpublished observation) that the ER
and Golgi compartments of Schwann cells of transgenic
mice expressing the R142W Cx32 mutant appear normal
instead of taking on the distended morphology characteris-
tic of class II disorders and their murine models, including
Pelizaeus–Merzbacher disease (Gow and Lazzarini, 1996),
a1-anti-trypsin deficiency (Carlson et al., 1989), and congen-
ital hypothyroid goiter (Mayerhofer et al., 1988; Aridor and
Balch, 1999).
The absence of evidence of intracellular accumulation of
CMTX-linked Cx32 mutants does not, however, mandate
that they act as simple nulls. Several such mutants, includ-
ing E186K and R142W Cx32, have been shown to inhibit the
function of coexpressed WT Cx32 in paired Xenopus oocytes
(Bruzzone et al., 1994), transfected tissue culture cells (Omori
et al., 1996), and/or (in the case of R142W Cx32) transgenic
mice (Scherer et al., 1999). Bruzzone et al. (1994) have dem-
onstrated that E186K and R142W Cx32 also block the activity
of certain other, but not all, connexin family members. Be-
cause the Cx32 gene is subject to X inactivation (Scherer et
al., 1998), WT and mutant forms of Cx32 do not coexist
within the same cell in CMTX patients. Any physiologically
relevant interaction must therefore be between mutant Cx32
and a non-Cx32 connexin. Evidence for the existence of other
connexin species in myelinating Schwann cells has recently
been provided by Balice-Gordon et al. (1998), who demon-
strated the continued presence of a radial pathway for the
diffusion of a gap junction tracer through the incisures of
Schmidt–Lanterman in cx32-null mice. Because of their dom-
inant negative activity, it had been assumed that CMTX-
linked Cx32 mutants co-oligomerize with wild-type connex-
ins to form mixed connexons. We show here, however, that
the R142W and E186K Cx32 mutants are not capable of
assembling into connexons when expressed individually in
PC12 cells, raising the possibility that they act instead by
engaging wild-type connexins in some other type of com-
plex formation or by outcompeting the normal protein for
binding to an as yet unknown limiting factor required for
gap junction assembly or trafficking. The gain-of-function
activity of the R142W and E186K Cx32 mutants is therefore
distinct from that of dominant nephrogenic diabetes insipi-
dus-causing mutations of aquaporin-2, which is closely cor-
related with their ability to assemble into homo-oligomers in
the absence of the wild-type protein (Kamsteeg et al., 1999).
Investigation of the mechanism and potential physiological
significance of the dominant negative activity of R142W
Cx32 and other CMTX-linked mutants awaits the definitive
identification of the connexin species that coexist with Cx32
in myelinating Schwann cells.
Quality Control of Connexins in the Secretory
Pathway as Revealed by CMTX-linked
Cx32 Mutants
The selective recognition, retention, and degradation of in-
correctly folded proteins in the secretory pathway are me-
diated by a variety of mechanisms that have been referred to
as the cell’s quality control system (Hammond and Hele-
nius, 1995). The studies presented here indicate that there
are at least three quality control processes that prevent ab-
normal connexin molecules from traversing the secretory
pathway. The earliest quality control checkpoint we have
identified is in the ER, where all of the E208K mutant was
recognized as non-native and directed to rapid, proteasome-
mediated degradation. Under all conditions tested, E208K
Cx32 was detectable solely within the ER even if its turnover
was slowed using inhibitors of the proteasome. ER localiza-
tion of this mutant therefore appears to be due to true
retention rather than to rapid degradation or to retrieval
from the intermediate compartment or Golgi complex. In
principle, ER retention could be due to one of three alterna-
tive processes (Kim and Arvan, 1998): 1) aggregation into
insoluble complexes too large to be incorporated into a
budding transport vesicle; 2) acquisition of an ER retention
determinant in an otherwise normally folded protein; or 3)
protein misfolding and consequent recognition by, and
binding to, an ER resident. Although the basis for the trans-
port block of E208K Cx32 is not yet known, the Triton X-100
solubility of this mutant and its inability to assemble into a
connexon render the first two mechanisms unlikely and
suggest instead a conformational defect consistent with the
third possibility.
Some of the R142W and E186K Cx32 molecules were
competent to pass through the checkpoint in the ER and
entered the Golgi region. Because neither mutant assembles
into connexons, the criteria for ER exit, unlike those for other
multisubunit proteins (Hurtley and Helenius, 1989), cannot
involve either the current or future oligomerization state.
Remarkably, these two point mutants were then subjected to
different post-ER quality control processes that prevented
unassembled connexin monomers from reaching the cell
surface. R142W Cx32 that exited the ER was transported to,
and degraded within, the endosome–lysosome system. In
contrast, post-ER pools of E186K Cx32 could not be detected
in lysosomes but instead underwent retrograde transport
from the Golgi region to the ER and remained sensitive to
inhibitors of proteasomal degradation. Turnover of E186K
Cx32 is therefore distinct from that of a mutant form of
asialoglycoprotein receptor H1 subunit described by Wahl-
berg et al. (1995), which also exits the ER and is unaffected by
lysosomal inhibitors but does not appear to return to the ER
even after a 3.5-h chase with cycloheximide. Given its role in
the degradation of other proteins at the ER, it is possible that
the translocon mediates the dislocation of mutant connexins
from the membrane into the proteasome (Plemper and Wolf,
1999). Such a process would require E186K Cx32 molecules
to post-translationally reengage this channel after their re-
turn from post-ER compartments.
Degradation at the ER is also a property of wild-type
connexins. As determined by pulse–chase analysis, newly
synthesized WT Cx32 and Cx43 molecules continue to un-
dergo rapid, proteasome inhibitor-sensitive turnover even if
their exit from the ER is blocked with BFA (Figure 6). In this
respect connexins resemble the CFTR, up to ;80% of which
is destroyed by proteasome-mediated degradation in a pre-
Golgi compartment (Jensen et al., 1995; Ward et al., 1995).
Conformational maturation of the CFTR appears to be a
slow and inefficient event involving interactions between
domains in spatially distant regions of this polytopic mem-
brane protein. Errors in this process are believed to result in
a large population of incompletely folded CFTR molecules
that are recognized by the ER degradation machinery
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(Zhang et al., 1998). Cysteine scanning mutagenesis has in-
dicated that the tertiary structure of connexins may also be
unusually complex, with multiple transmembrane domains
contributing to the channel pore (Oh et al., 1997; Zhou et al.,
1997). One possibility is that folding of wild-type connexins
is slow relative to the rate of connexin degradation, resulting
in the turnover of a large fraction of newly synthesized
connexin molecules before they can achieve a conformation
permissive for transport to the cell surface. Although such
inefficiency would seem counterproductive, it would serve
to limit the number of properly folded and therefore poten-
tially assembly competent connexin molecules in the early
secretory pathway under physiological levels of connexin
expression. This would reduce the possibility of premature
formation of gap junctional plaques within intracellular
membranes, as has been observed after high-level overex-
pression of exogenous Cx32 in baby hamster kidney trans-
fectants (Kumar et al., 1995).
A common assay for assessing connexin function is the
formation of intercellular channels between paired Xenopus
oocytes injected with connexin-encoding cRNA. Bruzzone et
al. (1994) have studied both the E186K and the R142W
CMTX-linked Cx32 mutants in this system and found, as we
have in PC12 cells, that these mutants are inactive. Surpris-
ingly, both mutants appeared to accumulate at oocyte inter-
faces in a manner immunohistochemically indistinguishable
from functional WT Cx32 and thus very different from the
intracellular localization pattern observed in PC12 transfec-
tants or (in the case of R142W Cx32) transgenic mice (Scherer
et al., 1999). The basis for the apparent mislocalization of the
E186K and R142W Cx32 mutants in Xenopus oocytes is un-
known. Unlike the DF508 mutant of the CFTR (Denning et
al., 1992), the trafficking defects of the CMTX-linked Cx32
mutants examined cannot be corrected by incubating PC12
cells at the lower temperatures (#27°C) at which oocytes are
maintained (our unpublished results). The slower rate of
connexin degradation in oocytes relative to mammalian cells
(Zhou et al., 1999) is also unlikely to be a factor, in that
decreasing the rate of mutant Cx32 turnover in PC12 cells
with proteasome inhibitors did not induce cell surface local-
ization. Transport to the plasma membrane after exogenous
expression in oocytes, but not in mammalian cells, has also
been described for some mutants of the aquaporin-2 water
channel (Tamarappoo and Verkman, 1998; Yang et al., 1999).
Although it is conceivable that oocytes are more permissive
than mammalian cells in allowing misfolded proteins to
traverse the secretory pathway, it is difficult to imagine how
they would avoid the toxic consequences of inappropriate
localization of nonfunctional or malfunctioning proteins. A
more likely explanation for the cell surface expression of the
E186K and R142W Cx32 mutants observed by Bruzzone et al.
(1994) is that oocytes have a normal quality control system
but that the capacity of this system is exceeded by the very
high expression levels routinely achieved after injection of
cRNA into these enormous cells. Leakage of mutant or oth-
erwise improperly folded membrane proteins to the cell
surface after supraphysiological overexpression has previ-
ously been described even in mammalian cells (Maimone
and Merlie, 1993; Cheng et al., 1995). An alternative possi-
bility arises from a study by Mulders et al. (1998) in which an
aquaporin-2 mutant that by immunofluorescence micros-
copy appeared to be efficiently transported to the cell surface
when expressed in Xenopus oocytes was shown by electron
microscopy to instead be localized to Golgi stacks concen-
trated immediately beneath the oolemma. Lack of resolution
between the oolemma and Golgi is, however, unlikely to
account for the observations of Bruzzone et al. (1994), be-
cause intracellular retention would not be expected to lead
to the reported concentration of the E186K and R142W Cx32
mutants at regions of cell–cell contact.
Relevance to Other Connexin-related Disorders
Following the identification of Cx32 mutations in CMTX
patients, additional human diseases have been genetically
linked to members of the connexin family (Kelsell et al., 1997;
Richard et al., 1998; Shiels et al., 1998; Xia et al., 1998; Mackay
et al., 1999). In light of our current studies, it is particularly
intriguing that an R to W substitution in position 143 of
Cx26, which corresponds to R142 in Cx32, is associated with
nonsyndromic deafness (Brobby et al., 1998) and that an
E183K mutation in Cx31 (equivalent to E186K in Cx32) is
found in individuals with autosomal dominant hearing im-
pairment (Xia et al., 1998). It is therefore anticipated that
some of the findings reported here will be applicable to
disease-causing mutations in other connexins.
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